Tag: BMO Capital
-
Okta About to Refill its Bearish Gap
On March 2, we noted, “Keep an eye on Okta (OKTA). After Cowen analysts upgraded the stock to an outperform rating from market perform, with a $70 price target, the stock took off. Since the start of 2023, OKTA ran from about $60 to $81 so far. From here, we’d like to see it initially…
-
Weakness in Bristol Myers Squibb is a Big Opportunity
Bristol Myers Squibb (BMY) is on the move. After plummeting from about $68 to a low of $54.60, the oversold stock is just starting to pivot higher. In fact, from a current price of $58.65, we’d like to see the stock retest $68. Helping, the company just boosted its quarterly dividend to 54 cents a…